Quirks associated with CT measurement can give a false impression of lung-tumor growth, according to a new study published in the Journal of Clinical Oncology.
Quirks associated with CT measurement can give a false impression of lung-tumor growth, a new study published online July 5 in the Journal of Clinical Oncology concludes.
Gregory J. Riely, MD, PhD, led a Memorial Sloan-Kettering Cancer Center team in the work. The study involved 33 patients with late-stage non-small-cell lung cancer who consented to undergo two chest computed tomography exams within 15 minutes of each other. Such scans would normally happen months apart, and scans indicating even slight tumor growth can be part of the clinical justification for additional treatment.
All the patients had lesions larger than 1 cm in diameter. Three radiologists measured the diameter of the target lesions on the two scans side-by-side.
The radiologists found that 57 percent of the apparent changes exceeded 1 mm in magnitude, and 33 percent of the changes exceeded 2 mm. The median increase and decrease in tumor measurements was 4.3 percent and minus-4.2 percent, respectively, and ranged from 23 percent shrinkage to 31 percent growth.
Measurement changes were within plus-or-minus 10 percent for 84 percent of measurements. Three percent of measurements met the 20-percent growth criteria for progression according to Response Evaluation Criteria in Solid Tumors (RECIST). Small lesions had greater variability measurement change.
Riely and colleagues concluded that apparent changes in tumor diameter exceeding 1 to 2 mm are common upon immediate reimaging, and that radiologists should be aware that apparent size differences of less than 10 percent may stem from the inherent variability of reimaging.
“Caution should be exercised in interpreting the significance of small changes in lesion size in the care of individual patients and in the interpretation of clinical trial results,” the researchers concluded.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.